UV Flu Technologies Expands Its International Footprint

CENTERVILLE, Mass., Nov. 10, 2011 /PRNewswire/ -- UV Flu Technologies, Inc.(OTCBB: UVFT) (the "Company") is pleased to announce it has expanded its International Distribution by adding representation in Oman, and Sri Lanka, while continuing to expand its relationship with the Company's Distributor in India, Ormed Systems, a leader in medical equipment sales and services throughout India, as well as other parts of the world. The Company continues efforts in China, the Mideast, and has begun talks with representation in South America.

"The market potential for our products outside of this Country is nothing short of extraordinary," said Jack Lennon, President of UV Flu Technologies. "Indoor air pollution in other parts of the world in many locations can be hundreds of times worse than what our EPA would qualify as unhealthy. Indoor air pollution has been found to have direct links to a variety of health problems, including, but not limited to, respiratory issues such as asthma, allergies, and pneumonia, sleep problems, low energy, diabetes, and even cardiovascular problems."

"We think many other countries are farther down the learning curve with respect to the importance of indoor air quality, and India and China are two of the biggest. We plan on supporting and expanding our international efforts, while launching some huge initiatives domestically. To this end, the Company has begun evaluating its options with respect to increasing its production capabilities, and feels that the sales of its products in 2012 could be many times those of 2011," said Mr. Lennon.

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.